AzTrials
AzTrials

Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)Phase 1NCT03649165

A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants

A Phase 1 study testing Treatment A, Treatment B and Treatment C in people with Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs) and Healthy Participants, run by AstraZeneca at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study will evaluate bioavailability and food effect of selumetinib (AZD6244) in healthy male participants. A total of 24 healthy male participants will be included to ensure at least 20 evaluable participants. Read more about this study

Who is it for?
Ages 18 to 45 years, men onlyHealthy volunteers can take part
What is being tested?
Treatment A, Treatment B and Treatment C
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
24 participants
Where
1 siteUnited States
Study dates
5 Sep 2018to 21 Oct 2018
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • Men only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Provision of signed and dated, written informed consent before any study-specific procedures.
  • Healthy male participants aged 18 to 45 years (inclusive) with suitable veins for cannulation or repeated venipuncture.
  • Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg.
  • Participants is able to consume a low-fat meal within a 30-minute period.
  • Participants has a creatinine clearance (CRCL) greater than 50 mL/min using Cockcroft-Gault formula.
  • Participants is willing to comply with contraception requirements as described below:
Show all 14Show fewer
  • Male participants with sexual partners who can become pregnant (i.e., women of childbearing potential) must use 2 highly-effective methods of contraception, one of which must be a barrier method (condom with spermicide) from the time of the first administration of the IMP until 12 weeks after the last administration of the IMP to avoid pregnancy and/or potential adverse effects on the developing embryo.
  • Participants with sexual partners who are pregnant must use an effective method of contraception (barrier method) from the time of the first administration of the IMP until 12 weeks after the last administration of the IMP.
  • Participants must avoid sperm donation during the study and for 12 weeks after the last administration of the IMP.
  • Reliable methods of contraception must be used consistently and correctly.
  • Reliable methods of contraception for participants include: Use of barrier methods (condom and spermicide) for the duration of the study until 12 weeks after the last administration of the IMP.
  • Acceptable methods for participants partners include:
  • Use of implants, injectables and combined oral contraceptives (must be used in combination with a barrier method of contraception)
  • Use of intrauterine devices (must be used in combination with a barrier method of contraception)

Who cannot join

  • Participants of Japanese, non-Japanese Asian or Indian ethnicity.
  • Participants has any one parent or grandparent (maternal or paternal) that was Japanese or non-Japanese Asian (e.g., China, Taiwan, Korea, Philippines, Thailand, Vietnam and Malaysia) or Indian.
  • History or presence of central serous retinopathy or retinal vein thrombosis, IOP greater than 21 mmHg or uncontrolled glaucoma.
  • History of any clinically significant disease or disorder which, in the opinion of the PI, may put the participant at risk because of participation in the study, influence the result of the study or influence the participants ability to participate in the study.
  • Participant has ophthalmologic conditions as follows:
  • Current or past history of central serous retinopathy/retinal pigment epithelial detachment or retinal vein occlusion.
Show all 38Show fewer
  • Intra-ocular pressure > 21 mmHg or uncontrolled glaucoma (irrespective of IOP).
  • Participant has any cardiac conditions as follows:
  • Uncontrolled hypertension (BP ≥ 150/95 mmHg despite medical therapy).
  • Acute coronary syndrome within 6 months before starting treatment.
  • Uncontrolled Angina - Canadian Cardiovascular Society grade II-IV despite medical therapy.
  • Symptomatic heart failure New York Heart Association (NYHA) Class II-IV, prior or current cardiomyopathy, or severe valvular heart disease.
  • Prior or current cardiomyopathy including but not limited to the following: 1) Known hypertrophic cardiomyopathy.
  • 2) Known arrhythmogenic right ventricular cardiomyopathy. 3) Previous moderate or severe impairment of LVEF < 45% on echocardiography even if full recovery has occurred.
  • Left ventricular ejection fraction below the lower limit of normal (LLN) or < 55% measured by ECHO at the Screening Visit.
  • Severe valvular heart disease.
  • Atrial fibrillation with a ventricular rate > 100 beats per minute (bpm) on ECG at rest.
  • QTcF > 450 ms or other factors that increase the risk of QT prolongation.
  • Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMP.
  • Any clinically relevant abnormal findings in physical examination, hematology, clinical chemistry, urinalysis, vital signs or ECG at the Screening Visit, which in the opinion of the PI, may put the participant at risk because of his participation in the study. Test may be repeated twice at the discretion of the Investigator if abnormal.
  • Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody.
  • A suspected/manifested infection according to the International Air Transport Association (IATA) Categories A and B infectious substances.
  • History of, or current alcohol or drug abuse, as judged by the principal investigator (PI).
  • Participation in another clinical study (investigational product administered within 30 days before the Screening Visit, or participation in a method development study [no drug] 30 days before the Screening Visit). Participation is defined as the completion of a treatment related visit.
  • Planned in-patient surgery, dental procedure or hospitalization during the study.
  • Plasma donation within 30 days of the Screening Visit or any blood donation/loss more than 500 mL during the 90 days before the Screening Visit.
  • A definite or suspected personal history of intolerance or hypersensitivity to drugs and/or their excipients, judged to be clinically relevant by the PI.
  • Known severe hypersensitivity to selumetinib or acetaminophen or any excipient of these medicinal products or history of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib.
  • Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the 90 days before the Screening Visit.
  • Positive screen for drugs of abuse, alcohol or cotinine at the Screening Visit or on each admission to the Clinical Unit or positive screen for alcohol on each admission to the Clinical Unit.
  • Use of drugs with enzyme-inducing properties such as St John's Wort within 4 weeks before the first administration of IMP.
  • Use of any prescribed medicine and over-the-counter (OTC) drugs (including herbal remedies, vitamins and minerals) within 2 weeks or 5 times the half-life, whichever is the longer, of the respective drug before Day -1 or Treatment Period 1. No medications known to prolong the QT/QTc interval are allowed.
  • Excessive intake of caffeine-containing drinks or food e.g., coffee, tea, chocolate, Red Bull or cola (more than 6 units of caffeine per day). One caffeine unit is contained in the following items: 1 (6 oz) cup of coffee, 2 (12 oz) cans of cola, 1 (12 oz) cup of tea, ½ (4 oz) cup of energy drink (e.g., Red Bull) or 3 oz of chocolate.
  • Known or suspected history of alcohol or drug abuse or excessive intake of alcohol as judged by the PI.
  • Involvement of any AstraZeneca, PAREXEL or Clinical Unit employee or their close relatives.
  • Participants who have previously been randomized to treatment in the current study.
  • Judgment by the PI that the participant should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions and requirements.
  • Vulnerable participants , e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • Research Site

    Baltimore, Maryland, 21225

Other trials in United States

About this study

Official title: A Phase I, Open-label, Single-center Relative Bioavailability and Food Effect Randomized Crossover Study of New Granule and Capsule Formulations of Selumetinib (AZD6244) in Healthy Male Subjects

This study will evaluate bioavailability and food effect of selumetinib (AZD6244) in healthy male participants. A total of 24 healthy male participants will be included to ensure at least 20 evaluable participants. The study is divided in 2 study parts; the same participants will participate in both parts of the study. Part 1 of the study is to investigate the pharmacokinetics (PK) of the selumetinib granule compared to the PK of selumetinib capsule, when administered with water under the fasted conditions. Part 2 of the study is to investigate the PK of selumetinib granule and capsule under fed conditions. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration.

Read the detailed description

This study will be a 2-part, open-label, single-center relative bioavailability and food effect randomized crossover study of new granule and capsule formulations of selumetinib. A total of 24 healthy male participants aged between 18 to 45 years (inclusive), will be included to ensure at least 20 evaluable participants. The study is divided in 2 study parts; the same participants will participate in both parts of the study.

Part 1 of the study is designed to investigate the PK of the selumetinib granule compared to the PK of selumetinib capsule, when administered with water under the fasted conditions. Part 2 of the study is designed to investigate the PK of selumetinib granule and capsule under fed conditions. Participants will consume a low-fat, low-calorie meal. Thirty minutes after the start of the meal, selumetinib will be administered to the participants. In all treatment periods, participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying. The study will also assess the palatability of the selumetinib granule in both parts of the study.

Each participant will receive the following treatments:

  • Treatment A: 25 mg granule, fasted state
  • Treatment B: 50 mg capsule, fasted state
  • Treatment C: 25 mg granule, fed state
  • Treatment D: 50 mg capsule, fed state Participant will be randomly assigned to 1 of 4 treatment sequences. In all cases the treatments in Part 1 will be administered before the treatments in Part 2. The study will comprise of a screening period of maximum 28 days. Four treatment periods during which participants will be resident from the day before dosing (Day -1) until at least 48 hours after dosing; discharged on the morning of Day 3. A follow-up visit, will be within 7 to 10 days after the last dose of investigational medicinal product (IMP). There will be a minimum washout period of at least 5 days between each IMP administration. Each participant will be involved in the study for approximately 8 to 9 weeks.
Being tested
Treatment A, Treatment B, Treatment C, Treatment D, Acetaminophen
Keywords
MEK Inhibitor, Selumetinib capsule, Selumetinib granule, PK, Bioavailibilty, Crossover study, Open-label, Food effect
Medical subject headings
Neurofibromatosis 1

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Treatment ADrug

    During Part 1 of the study, participants will receive single doses of selumetinib 25 mg granule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.

  • Treatment BDrug

    During Part 1 of the study, participants will receive single doses of selumetinib 50 mg capsule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.

  • Treatment CDrug

    During Part 2 of the study, participants will receive single doses of selumetinib 25 mg granule under fed conditions. Following an overnight fast of at least 10 hours, participants will start consumption of the recommended meal within 30 minutes before administration of the IMP. Participants will be required to consume the entire meal in 30 minutes or less; however, the IMP should be administered 30 minutes after start of the meal. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose, where after a meal may be provided.

  • Treatment DDrug

    During Part 2 of the study, participants will receive single doses of selumetinib 50 mg capsule under fed conditions. Following an overnight fast of at least 10 hours, participants will start consumption of the recommended meal within 30 minutes before administration of the IMP. Participants will be required to consume the entire meal in 30 minutes or less; however, the IMP should be administered 30 minutes after start of the meal. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose, where after a meal may be provided.

  • AcetaminophenDrug

    Participants will receive a single 500mg dose of acetaminophen at the same time.

Study groups in NCT03649165
Study groupRoleWhat they receive
Treatment Sequence 1ExperimentalParticipants will receive Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 1, Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 2, Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 3, and Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
Receives: Drug: Treatment A; Drug: Treatment B; Drug: Treatment C; Drug: Treatment D; Drug: Acetaminophen
Treatment Sequence 2ExperimentalParticipants will receive Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 1, Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 2, Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 3 and Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
Receives: Drug: Treatment A; Drug: Treatment B; Drug: Treatment C; Drug: Treatment D; Drug: Acetaminophen
Treatment Sequence 3ExperimentalParticipants will receive Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 1, Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 2, Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 3 and Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
Receives: Drug: Treatment A; Drug: Treatment B; Drug: Treatment C; Drug: Treatment D; Drug: Acetaminophen
Treatment Sequence 4ExperimentalParticipants will receive Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 1, Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 2, Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 3 and Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
Receives: Drug: Treatment A; Drug: Treatment B; Drug: Treatment C; Drug: Treatment D; Drug: Acetaminophen

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Selumetinib and N-desmethyl selumetinib plasma PK parameter: Dose normalized area under plasma concentration-time curve from time zero to infinity (AUC/D)

    To compare the AUC/D of the new selumetinib granule formulation with selumetinib capsule formulation in fasted state.

    Measured: At pre-dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose(Days -1 to 3)

  2. Selumetinib and N-desmethyl selumetinib plasma PK parameter: Dose normalized area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUClast/D)

    To compare the AUClast/D of the new selumetinib granule formulation with selumetinib capsule formulation in fasted state.

    Measured: At pre-dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose(Days -1 to 3)

  3. Selumetinib and N-desmethyl selumetinib plasma PK parameter: Dose normalized maximum observed plasma concentration (Cmax/D)

    To compare the Cmax/D of the new selumetinib granule formulation with selumetinib capsule formulation in fasted state.

    Measured: At pre-dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose(Days -1 to 3)

  4. Selumetinib and N-desmethyl selumetinib plasma PK parameter: Fraction of administered selumetinib granule dose systemically available relative to the capsule reference (Frel)

    To compare the Frel. of the new selumetinib granule formulation with selumetinib capsule formulation in fasted state.

    Measured: At pre-dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose(Days -1 to 3)

Secondary outcomes (49)

  1. Selumetinib and N-desmethyl selumetinib plasma PK parameter: Area under plasma concentration time curve from time zero to infinity (AUC)

    To compare AUC of selumetinib capsule fasted versus capsule low-fat fed state.

    Measured: At pre-dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose(Days -1 to 3)

  2. Selumetinib and N-desmethyl selumetinib plasma PK parameter: Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUClast)

    To compare AUClast of selumetinib capsule fasted versus capsule low-fat fed state.

    Measured: At pre-dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose (Days -1 to 3)

  3. Selumetinib and N-desmethyl selumetinib plasma PK parameter: Area under the plasma concentration-time curve from zero to 12 hours post-dose [AUC(0-12)]

    To compare AUC (0-12) of selumetinib capsule fasted versus capsule low-fat fed state.

    Measured: At pre-dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose (Days -1 to 3)

  4. Selumetinib and N-desmethyl selumetinib plasma PK parameter: Maximum observed plasma concentration (Cmax)

    To compare Cmax of selumetinib capsule fasted versus capsule low-fat fed state.

    Measured: At pre-dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose (Days -1 to 3)

  5. Selumetinib and N-desmethyl selumetinib plasma PK parameter: Ratio of AUC in fed state to AUC in the fasted state (FRAUC)

    To compare FRAUC of selumetinib capsule fasted versus capsule low-fat fed state.

    Measured: At pre-dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose (Days -1 to 3)

  6. Selumetinib and N-desmethyl selumetinib plasma PK parameter: Ratio of Cmax in fed state to Cmax in the fasted state (FRCmax)

    To compare FRCmax of selumetinib capsule fasted versus capsule low-fat fed state.

    Measured: At pre-dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose (Days -1 to 3)

  7. Selumetinib and N-desmethyl selumetinib plasma PK parameter: Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½λz)

    To compare t½λz of selumetinib capsule fasted versus capsule low-fat fed state.

    Measured: At pre-dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose (Days -1 to 3)

  8. Selumetinib and N-desmethyl selumetinib plasma PK parameter: Time to reach maximum observed plasma concentration (tmax)

    To compare tmax of selumetinib capsule fasted versus capsule low-fat fed state.

    Measured: At pre-dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose (Days -1 to 3)

  9. Selumetinib and N-desmethyl selumetinib plasma PK parameter: Terminal elimination rate constant (λz)

    To compare λz of selumetinib capsule fasted versus capsule low-fat fed state.

    Measured: At pre-dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose (Days -1 to 3)

  10. Selumetinib plasma PK parameters: Apparent total body clearance of drug from plasma after extravascular administration (parent drug only) (CL/F)

    To compare CL/F of selumetinib capsule fasted versus capsule low-fat fed state.

    Measured: At pre-dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose (Days -1 to 3)

  11. Selumetinib plasma PK parameters: Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)

    To compare Vz/F of selumetinib capsule fasted versus capsule low-fat fed state.

    Measured: At pre-dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose (Days -1 to 3)

  12. Selumetinib and N-desmethyl selumetinib plasma PK parameter: AUC

    To compare AUC of selumetinib granule fasted versus granule low-fat fed state.

    Measured: At pre-dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose (Days -1 to 3)

  13. Selumetinib and N-desmethyl selumetinib plasma PK parameter: AUClast

    To compare AUClast of selumetinib granule fasted versus granule low-fat fed state.

    Measured: At pre-dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose (Days -1 to 3)

  14. Selumetinib and N-desmethyl selumetinib plasma PK parameter: AUC(0-12)

    To compare AUC (0-12) of selumetinib granule fasted versus granule low-fat fed state.

    Measured: At pre-dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose (Days -1 to 3)

  15. Selumetinib and N-desmethyl selumetinib plasma PK parameter: Cmax

    To compare Cmax of selumetinib granule fasted versus granule low-fat fed state.

    Measured: At pre-dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose (Days -1 to 3)

  16. Selumetinib and N-desmethyl selumetinib plasma PK parameter: FRAUC

    To compare FRAUC of selumetinib granule fasted versus granule low-fat fed state.

    Measured: At pre-dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose (Days -1 to 3)

  17. Selumetinib and N-desmethyl selumetinib plasma PK parameter: FRCmax

    To compare FRCmax of selumetinib granule fasted versus granule low-fat fed state.

    Measured: At pre-dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose (Days -1 to 3)

  18. Selumetinib and N-desmethyl selumetinib plasma PK parameter: t½λz

    To compare t½λz of selumetinib granule fasted versus granule low-fat fed state.

    Measured: At pre-dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose (Days -1 to 3)

  19. Selumetinib and N-desmethyl selumetinib plasma PK parameter: tmax

    To compare tmax of selumetinib granule fasted versus granule low-fat fed state.

    Measured: At pre-dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose (Days -1 to 3)

  20. Selumetinib and N-desmethyl selumetinib plasma PK parameter: λz

    To compare λz of selumetinib granule fasted versus granule low-fat fed state.

    Measured: At pre-dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose (Days -1 to 3)

  21. Selumetinib plasma PK parameters: CL/F

    To compare CL/F of selumetinib granule fasted versus granule low-fat fed state.

    Measured: At pre-dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose (Days -1 to 3)

  22. Selumetinib plasma PK parameters: Vz/F

    To compare Vz/F of selumetinib granule fasted versus granule low-fat fed state.

    Measured: At pre-dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose (Days -1 to 3)

  23. Taste questionnaire

    To assess palatability of selumetinib granule formulation. The standardized questionnaire will be administered to participants within 10 minutes following intake of selumetinib granule. Questionnaire about taste include sweet, salty, sour, bitter, metallic, and hot/spicy. Where 0 indicates not at all and 10 indicates extremely.

    Measured: At Days -1 to 3 (within 10 minutes following intake of selumetinib granule)

  24. Number of participants with adverse events (AEs)

    To assess the safety and tolerability of single doses of selumetinib in healthy participants.

    Measured: From the time of informed consent, throughout the treatment periods up to and including the Follow-up Visit (7 to 10 days after last dose)

  25. Vital signs (systolic blood pressure [BP])

    To assess systolic BP as a variable of safety and tolerability of single doses of selumetinib in healthy participants. Participants should be supine and at rest for at least 5 minutes before the measurements.

    Measured: Change from baseline up to follow-up/early termination visit (7 to 10 days after last dose)

  26. Vital signs (diastolic BP)

    To assess diastolic BP as a variable of safety and tolerability of single doses of selumetinib in healthy participants. Participants should be supine and at rest for at least 5 minutes before the measurements.

    Measured: Change from baseline up to follow-up/early termination visit (7 to 10 days after last dose)

  27. Pulse rate

    To assess pulse rate as a variable of safety and tolerability of single doses of selumetinib in healthy participants.

    Participants should be supine and at rest for at least 5 minutes before the measurements.

    Measured: Change from baseline up to follow-up/early termination visit (7 to 10 days after last dose)

  28. 12-lead electrocardiogram (ECG)

    To assess 12-lead ECG as variable of safety and tolerability of single doses of selumetinib in healthy participants. Participants should be supine and at rest 10 minutes before recording the ECG.

    Measured: From baseline up to follow-up/early termination visit (7 to 10 days after last dose)

  29. Number of participants with abnormal findings in physical examination

    To assess physical examination as a variable safety and tolerability of single doses of selumetinib in healthy participants.

    Measured: From baseline up to follow-up/early termination visit (7 to 10 days after last dose)

  30. Ophthalmic examinations

    To assess ophthalmic examination as a variable of safety and tolerability of single doses of selumetinib in healthy participants. Ophthalmic examination included best corrected visual acuity, intra-ocular pressure and slit-lamp fundoscopy.

    Measured: At screening Visit or on Day -1 of Treatment Period 1

  31. Laboratory assessments: hematology - Hemoglobin (Hb)

    To assess Hb as a variable of safety and tolerability of single doses of selumetinib in healthy participants.

    Measured: Change from baseline up to follow-up/early termination visit (7 to 10 days after last dose)

  32. Laboratory assessments: hematology - erythrocyte count

    To assess erythrocyte count as a variable of safety and tolerability of single doses of selumetinib in healthy participants.

    Measured: Change from baseline up to follow-up/early termination visit (7 to 10 days after last dose)

  33. Laboratory assessments: hematology: Platelet count

    To assess platelet count as a variable of safety and tolerability of single doses of selumetinib in healthy participants.

    Measured: Change from baseline up to follow-up/early termination visit (7 to 10 days after last dose)

  34. Laboratory assessments: hematology: leucocyte differential count (absolute count)

    To assess leucocyte differential count as a variable of safety and tolerability of single doses of selumetinib in healthy participants.

    Measured: Change from baseline up to follow-up/early termination visit (7 to 10 days after last dose)

  35. Laboratory assessments: hematology: leucocyte cell count

    To assess leucocyte cell count as variable of safety and tolerability of single doses of selumetinib in healthy participants.

    Measured: Change from baseline up to follow-up/early termination visit (7 to 10 days after last dose)

  36. Laboratory assessments:hematology - differential count

    To assess differential count of neutrophils, lymphocytes, monocyets, eosinophils and basophils) as a variable of safety and tolerability of single doses of selumetinib in healthy participants.

    Measured: Change from baseline up to follow-up/early termination visit (7 to 10 days after last dose)

  37. Laboratory assessments: Serum clinical chemistry - electrolytes

    To assess serum level of sodium, potassium, magnesium and phosphate as a variable of safety and tolerability of single doses of selumetinib in healthy participants.

    Measured: Change from baseline up to follow-up/early termination visit (7 to 10 days after last dose)

  38. Laboratory assessments: Serum clinical chemistry - urea nitrogen

    To assess urea nitrogen as a variable of safety and tolerability of single doses of selumetinib in healthy participants.

    Measured: Change from baseline up to follow-up/early termination visit (7 to 10 days after last dose)

  39. Laboratory assessments: Serum clinical chemistry - creatinine

    To assess creatinine as variable of safety and tolerability of single doses of selumetinib in healthy participants.

    Measured: Change from baseline up to follow-up/early termination visit (7 to 10 days after last dose)

  40. Laboratory assessments: Serum clinical chemistry: albumin

    To assess albumin as a variable of safety and tolerability of single doses of selumetinib in healthy participants.

    Measured: Change from baseline up to follow-up/early termination visit (7 to 10 days after last dose)

  41. Laboratory assessments: Serum clinical chemistry: Total Calcium

    To assess total calcium as a variable of safety and tolerability of single doses of selumetinib in healthy participants.

    Measured: Change from baseline up to follow-up/early termination visit (7 to 10 days after last dose)

  42. Laboratory assessments: Serum clinical chemistry: Total protein

    To assess total protein as a variable of safety and tolerability of single doses of selumetinib in healthy participants.

    Measured: Change from baseline up to follow-up/early termination visit (7 to 10 days after last dose)

  43. Laboratory assessments: Serum clinical chemistry: Total bilirubin

    To assess total bilirubin as a variable of safety and tolerability of single doses of selumetinib in healthy participants.

    Measured: Change from baseline up to follow-up/early termination visit (7 to 10 days after last dose)

  44. Laboratory assessments: Serum clinical chemistry: Creatine phosphokinase (CPK)

    To assess CPK as a variable of safety and tolerability of single doses of selumetinib in healthy participants.

    Measured: Change from baseline up to follow-up/early termination visit (7 to 10 days after last dose)

  45. Laboratory assessments: Serum clinical chemistry: Troponin (isoform as per institutional norm)

    To assess troponin as a variable of safety and tolerability of single doses of selumetinib in healthy participants.

    Measured: Change from baseline up to follow-up/early termination visit (7 to 10 days after last dose)

  46. Laboratory assessments: Serum clinical chemistry - Liver enzymes

    To assess serum of Alkaline phosphatase (ALP), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST) and Gamma glutamyl transpeptidase (GGT) as a variable of safety and tolerability of single doses of selumetinib in healthy participants.

    Measured: Change from baseline up to follow-up/early termination visit (7 to 10 days after last dose)

  47. Laboratory assessments: Clinical urinalysis - glucose

    To assess urine glucose as a variable of safety and tolerability of single doses of selumetinib in healthy participants.

    Measured: Change from baseline up to follow-up/early termination visit (7 to 10 days after last dose)

  48. Laboratory assessments: Clinical Urinalysis - protein

    To assess urine protein as a variable of safety and tolerability of single doses of selumetinib in healthy participants.

    Measured: Change from baseline up to follow-up/early termination visit (7 to 10 days after last dose)

  49. Laboratory assessments: Clinical Urinalysis - blood

    To assess urine blood as a variable of safety and tolerability of single doses of selumetinib in healthy participants.

    If urinalysis is positive for blood, a microscopy test will be performed to assess RBC, white blood cell [WBC], casts [cellular, granular, hyaline]).

    Measured: Change from baseline up to follow-up/early termination visit (7 to 10 days after last dose)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Aug 2018
  2. Study start5 Sep 2018
  3. Primary completion21 Oct 2018
  4. Study completion21 Oct 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
24 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03649165
Sponsor's protocol ID
D1532C00089
Status last verified
Nov 2018
First submitted
24 Aug 2018
Last updated
8 Nov 2018
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Cohen-Rabbie S, Mattinson A, So K, Wang N, Goldwater R. A Phase I, Open-label, Randomized, Crossover Study of the Relative Bioavailability of Capsule and Granule Formulations of Selumetinib. Clin Ther. 2022 Apr;44(4):565-576. doi: 10.1016/j.clinthera.2022.02.009. Epub 2022 Apr 9.

    PubMed 35410754

  • Cohen-Rabbie S, Mattinson A, So K, Wang N, Goldwater R. Effect of food on capsule and granule formulations of selumetinib. Clin Transl Sci. 2022 Apr;15(4):878-888. doi: 10.1111/cts.13209. Epub 2022 Feb 15.

    PubMed 35170228

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Treatment A, Treatment B and Treatment C in people with Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs) and Healthy Participants, run by AstraZeneca at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 14 inclusion and 38 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Nov 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Selumetinib and N-desmethyl selumetinib plasma PK parameter: Dose normalized area under plasma concentration-time curve from time zero to infinity (AUC/D) (time frame: At pre-dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose(Days -1 to 3)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03649165, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Nov 2018.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in